Please assess the completion status of the following clinical trial:

Trial Title: Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects ≥ 18 years of age at time of study entry.~2. Fasting LDLc at screening.~3. Fasting triglycerides at screening.~4. Body weight \> 50 kg and a body mass index (BMI) between 19 and 35.~Exclusion Criteria:~1. Treatment/change in treatment with medications known to influence HDLc, LDLc and total cholesterol concentrations~2. Planned life-style changes during the study period like increasing aerobic exercise activity, attempting to lose body weight or changing the smoking status.~3. History of autoimmune diseases.~4. History of malignancy~5. Active or passive vaccination~6. Blood donation~7. History of severe hypersensitivity reactions and anaphylaxis.~8. History of allergic bronchial asthma.~9. Acquired or hereditary immunodeficiency.~10. Prior and/or current treatment with immune modulating drugs:~11. Subject has taken prescription lipid-regulating drugs~12. Treatment prior to screening with the following drugs: vitamin A derivatives and retinol derivatives for dermatologic treatment or any other drug known to influence cholesterol Levels~13. Infection with the human immunodeficiency Virus,Hepatitis B (HBsAg) or Hepatitis C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- AFFITOPE® AT04A+adjuvant (Type: EXPERIMENTAL): 3 injections of 15µg AFFITOPE® AT04A+adjuvant once every 4 weeks and 1 boost immunization at a dose of 75μg, which will be applied one year after the 3rd immunization
- AFFITOPE® AT06A+adjuvant (Type: EXPERIMENTAL): 3 injections of 15µg AFFITOPE® AT06A+adjuvant once every 4 weeks and 1 boost immunization at a dose of 75μg, which will be applied one year after the 3rd immunization
- Adjuvant without active component (Type: PLACEBO_COMPARATOR): 3 injections of Placebo once every 4 weeks and 1 boost immunization which will be applied one year after the 3rd immunization

Based on this trial design, predict the completion outcome and termination type (if applicable).